Results 191 to 200 of about 249,629 (285)

Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis. [PDF]

ACG Case Rep J
Moghe R, Mathew AJ, Choi D, Rubin DT.
europepmc   +1 more source

Shaping the research agenda of pediatric gastroenterology, hepatology, and nutrition: The proposal from an Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) expert group

JPGN Reports, EarlyView.
Abstract The Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) recognized the need to define research priorities and identify knowledge gaps to guide future investigations in pediatric digestive health. Following international examples, SIGENP aimed to provide a structured framework that aligns scientific innovation with ...
Carlo Agostoni, Daniele Alberti, Renata Auricchio, Maria Elisabetta Baldassarre, Osvaldo Borrelli, Matteo Bramuzzo, Teresa Capriati, Carlo Catassi, Sabrina Cenni, Marco Crocco, Salvatore Cucchiara, Luigi Dall'Oglio, Paola De Angelis, Marco Deganello Saccomani, Fabiola Di Dato, Angelo Di Giorgio, Antonella Diamanti, Valeria Dipasquale, Enrico Felici, Ruggiero Francavilla, Valentina Giorgio, Luigi Greco, Raffaele lorio, Flavio Labriola, Paolo Lionetti, Elena Lionetti, Giuseppe Maggiore, Monica Malamisura, Claudia Mandato, Antonio Marseglia, Emanuele Nicastro, Lorenzo Norsa, Salvatore Oliva, Licia Pensabene, Elena Sofia Pieri, Paolo Quitadamo, Giusy Ranucci, Sara Renzo, Claudio Romano, Silvia Salvatore, Luca Scarallo, Maria Immacolata Spagnuolo, Annamaria Staiano, Caterina Strisciuglio, Renato Tambucci, Riccardo Troncone, Pietro Vajro   +46 more
wiley   +1 more source

Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry. [PDF]

J Gastroenterol Hepatol
González-Vivó M, Castro Senosiain B, Pérez-Martínez I, Barrio J, Vega Villaamil P, Caballol Oliva B, Pedrera Roman V, Piqueras Cano M, Rodríguez Moranta F, Iborra M, Casanova MJ, Gisbert JP, Tardillo Marin C, Ramos L, Urpi-Ferreruela M, Lorente Poyatos RH, Barreiro-de Acosta M, Belen Galipienso O, Bujanda L, Zabana Y, Murciano F, Domènech E, Márquez-Mosquera L.   +22 more
europepmc   +1 more source

The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis

JPGN Reports, EarlyView.
Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months).
Jonathan Van Hecke, Gigi Veereman, Koen Huysentruyt, Lucas Wauters, Jeremy Adler, Shehzad Saeed, Elisabeth De Greef, and the ImproveCareNow Pediatric IBD Learning Health System   +7 more
wiley   +1 more source

ULCERATIVE COLITIS

Annals of Surgery, 1928
openaire   +3 more sources

Direct clinician–pathologist multidisciplinary review and diagnostic revision in children with gastrointestinal disorders

JPGN Reports, EarlyView.
Abstract Accurate pediatric gastrointestinal (GI) diagnosis often depends on integrating clinical, endoscopic, and histopathologic information. We evaluated the impact of weekly face‐to‐face multidisciplinary team (MDT) meetings on diagnosis in children undergoing endoscopy or liver biopsy at a tertiary center.
Emma Dahl, Christa Bergheim, Irina Berger, Ralph Melchior, Andreas Jenke   +4 more
wiley   +1 more source

Assessing inflammation and predicting relapse in ulcerative colitis is more accurate when performed by IBD specialized gastroenterologists. [PDF]

Crohns Colitis 360
Alizadeh M, George LA, Abutaleb A, Cao W, Greenwald BD, Feldman HT, Hu S, Hudesman D, Onyimba F, Sarkar S, Stashek K, Sun K, Wong U, Zullow S, Axelrad J, Cross RK.   +15 more
europepmc   +1 more source

Insurance IQ: Demystifying health insurance for young people with inflammatory bowel disease

JPGN Reports, EarlyView.
ABSTRACT Many adolescents and young adults with inflammatory bowel disease (AYA‐IBD) lack essential health insurance knowledge. We evaluated an electronic health record (EHR)–based educational intervention to improve insurance literacy. From January to August 2025, AYA‐IBD who had completed a health insurance knowledge assessment and had an upcoming ...
Laura Gilligan, Jeannie S. Huang
wiley   +1 more source

Patient treatment engagement scale (PTES) for inflammatory bowel disease: exploring background factors. [PDF]

BMC Res Notes
Toyoshima H, Yashima C, Akase T, Koinuma M.   +3 more
europepmc   +1 more source

Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance

JPGN Reports, EarlyView.
Abstract Janus kinase inhibitors (JAKi) are increasingly used for refractory inflammatory bowel disease (IBD) in pediatric patients but are associated with significant dermatologic adverse effects. Acneiform eruptions have been reported in up to 30% of adults, with a greater incidence suspected in adolescents.
Tina H. Tran, Daniel Park, Regina‐Celeste Ahmad, Malika Goel, Sofia Verstraete, Sabina Ali   +5 more
wiley   +1 more source